Regina Day, Ph.D.

Regina M Day, Ph.D.

Name: Regina M Day, Ph.D.

USU Department of Primary Appointment: 
Pharmacology & Molecular Therapeutics
Title: 
Vice Chair
Faculty Rank: 
Professor
Location: 
Uniformed Services University of the Health Sciences, Bethesda, MD
Office Phone: 
(301) 295-3236

Education

A.B. Smith College, Northampton, MA, USA
Ph.D. Tufts University, Boston, MA, USA

Biography

Introduction and overview:
My laboratory is dedicated to understanding normal tissue repair processes and how the repair process is altered in fibrotic remodeling. Normal tissue regeneration for wound healing is a critical focus of research for the military as well as for the medical field in general. The long term goal of my laboratory is to understand the mechanism of fibrotic repair and to identify therapeutic agents to prevent and/or treat this disease. The lung provides an excellent model system for investigation, since it is uniquely sensitive to chemicals and radiation that produce well-defined stages of injury, inflammation, attempted repair, and repair failure/remodeling. Lung fibrosis is a progressive disease with no treatments and poor prognosis. Our laboratory uses in vivo animal models and in vitro primary cell cultures to systematically elucidate the mechanisms of tissue regeneration and fibrotic remodeling at the molecular, biochemical, cellular, and tissue levels.

Radiation countermeasures for the lung and hematopoietic systems and radiation biology:
• Radiation countermeasures for both the hematopoietic and lung tissues. Radiation-induced lung injury is a late effect of radiation, whereas hematopoietic injuries are an acute radiation injury. Because of the Department of Defense’s interest in protection against both acute and delayed injuries, we were requested to develop a murine model for both the hematopoietic and pulmonary injuries, and to test radiation countermeasures in both systems. My laboratory developed an animal model system incorporating both hematopoietic and lung radiation injuries. We have determined the mechanism of action of captopril protection in both tissues, as a part of the requirement for radiation countermeasure development under the Animal Rule for the FDA. We are currently expanding our testing of captopril in the minipig model of radiation acute injuries.
• My laboratory developed a cell culture system for studying the molecular mechanisms of radiation-induced senescence in normal (non-transformed, non-immortalized) cells. Our research demonstrated for the first time that normal lung and skin cells primarily undergo accelerated senescence, and not apoptosis, in response to radiation. We identified an early cellular response to radiation is the induction of insulin-like growth factor 1 (IGF-1) and the activation of its receptor (IGF-1R). These novel and provocative observations prompted us to hypothesize that senescence is the precipitating state for radiation pathology.

Hepatocyte growth factor (HGF) signaling for tissue repair and suppression of fibrosis:
• My laboratory has identified novel signaling pathways for HGF-induced normal tissue repair mechanisms. HGF expression is required for normal tissue repair, and HGF can redirect repair away from fibrotic remodeling to induce normal tissue regrowth. To understand how HGF can accomplish this, my research team investigated signal transduction mechanisms for HGF suppression of apoptosis in epithelial and endothelial cells that is induced during fibrosis. We next investigated the mechanisms by which HGF expression is suppressed during fibrotic remodeling. We recently uncovered a novel mechanism by which miRNA regulates HGF mRNA half-life under fibrotic conditions. This research led to the identification of potential novel anti-fibrotic treatment strategies.
• My laboratory developed a synthetic peptide based on other proteins that bind the HGF receptor, MET. The structural complexity of the full length HGF structure has prevented its development as a pharmaceutical agent, and full length HGF has not been successfully produced in sufficient quantities for clinical use. A patent was submitted by the USU/HJF JOTT based on these findings. Our laboratory currently aims to improve the design of this protein, to improve stability and increase receptor affinity.

Representative publications, projects, and/or deployments

  • 12/2016 – present Vice Chair USUHS School of Medicine Department of Pharmacology and Molecular Therapeutics
  • 7/2014- present Professor USUHS School of Medicine Primary Appointment Department of Pharmacology
  • 11/2014 Adjunct Professor Georgetown University School of Medicine Pulmonary, Critical Care, and Sleep Medicine
  • 2/2010- 7/2014 Associate Professor USUHS School of Medicine Primary Appointment Department of Pharmacology
  • 7/2004-1/2010 Tenure Track Assistant Professor USUHS School of Medicine Primary Appointment Department of Pharmacology
  • 1/2004-6/2004 Research Assistant Professor Georgetown Univ. School of Medicine Pulmonary, Critical Care, and Sleep Medicine
  • 8/1999-12/2004 Research Assistant Professor Tufts-New England Medical Ctr Pulmonary, Critical Care, and Sleep Medicine Div
  • Postdoctoral Fellow NIH, NCI, Lab of Cellular, Molecular Biology

Bibliography

  • Landauer, M.R., Harvey, A.J., Kaytor, M.D., Day, R.M. (2019) Mechanism and therapeutic window of a genistein nanosuspension to protect against hematopoietic-acute radiation syndrome. J. Radiat. Res. In press.
  • McCart, E.A., Lee, Y.H., Jha, J., Mungunsukh, O., Rittase, W.B., Summers, T.A., Muir, J., Day R.M. (2019) Delayed captopril administration mitigates hematopoietic injury in a murine model of total body irradiation. Sci Reports, 9: 2198.
  • Bylicky, M.A., Mueller, G.P., Day, R.M. (2019) Radiation resistance of normal human astrocytes: role of non-homologous end joining DNA repair activity. J Radiat Res. 60: 37-50.
  • Corey, S.J., Jha, J., McCart, E.A., Rittase, W.B., George, J., Mattapallil, J.J., Mehta, H., Ognoon, M., Bylicky, M.A., Summers, T.A., Day, R.M. (2018) Captopril mitigates splenomegaly and myelofibrosis in the Gata1low murine model of myelofibrosis. J Cell Mol Med, 22: 4274-4282.
  • Du, Y., Banas, R.A., McCart, E.A., George, J., Oakley, K., Han, Y., Landauer, M.R., Day, R.M. (2018) Effect of human amnion-derived multipotent progenitor cells on hematopoietic recovery after total body irradiation in C57BL/6 mice. Int J Radiat Res, 16:155-168.
  • Zhao*, J., Day*, R.M., Jin, J-Y., Quint, L., Williams, H., Ferguson, C., Yan, L., King, M., Albsheer, A., Matuszak, M., Kong, S-M. (2017) Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer. Oncotarget, 8: 97623-32.
  • McCart, E.A., Lombardini, E., Mog, S.R., Panganiban, R.A.M., Dickson, K.M., Mansur, R.A., Nagy, V., Kim, S-Y., Selwyn, R., Landauer, M.R., Darling, T.N., Day, R.M. (2017) Accelerated senescence in a murine model of radiation-induced skin injury. J Radiat Res, 58: 636-646.
  • Brzezniak, C., Oronsky, B., Trepel, J., Summers, T.A. Jr., Cabrales, P., Lee, M.J., Day, R., Jha, S., Caroen, S, Zeman, K, Ferr,y L, Harmer, C, Oronsky, N, Lybeck, M, Lybeck, HE, Brown, JF, Reid, T.R., Carter, C.A. RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Rep Oncol. 2017;10:276-280.
  • Mungunsukh, O., Lee, Y.H., Bottaro, D.P., Day, R.M. (2016) The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation. Cell Signal, 28, 1114-23.
  • Barshishat-Kupper, M., McCart E.A., Freedy, J.G., Tipton A.J., Nagy V., Kim, S.-Y., Landauer, M.R., Mueller G.P., Day R.M. (2015) Protein oxidation in the lungs of C57BL/6J mice following X-irradiation. Proteomes, 3, 249-265.